96 Scientists have unveiled a new chemotherapy compound that completely eradicated aggressive cancers in mice, raising hopes for safer and more powerful treatment options against drug-resistant tumours. The therapy, called LiPyDau, is a liposomal formulation of a highly toxic derivative of daunorubicin, a drug long used in cancer care. The findings were published in the journal Molecular Cancer. The study, led by researchers from Hungary and Austria, found that LiPyDau was able to destroy even the most resilient forms of breast, lung, and melanoma cancers in laboratory and animal models. What makes the findings striking is that LiPyDau achieved complete tumour regression in genetically engineered mice with triple-negative breast cancer, one of the most difficult cancers to treat. Traditional anthracycline drugs such as doxorubicin and daunorubicin have been central to cancer treatment for decades, but their use is often limited by severe side effects and the development of resistance. According to the research team, the new derivative, known as 2-pyrrolino-daunorubicin or PyDau, is up to 1,000 times more toxic to cancer cells than its predecessors. However, this potency also made it too dangerous for clinical use in its raw form. To overcome this, the scientists encapsulated PyDau within microscopic lipid bubbles known as liposomes, creating LiPyDau. This nanomedicine approach allowed the drug to circulate safely through the body and target tumour tissue while reducing damage to healthy cells. The liposomal coating effectively widened the drug’s safety margin and prevented the rapid toxicity that had previously limited its use. Tests on mice revealed that LiPyDau could shrink or completely eliminate tumours in models of breast, lung, and melanoma cancers. In triple-negative breast cancer models, even those resistant to existing chemotherapy, LiPyDau eradicated all tumours when administered in carefully controlled doses. Mice treated with the drug showed long-term survival with no detectable organ damage, demonstrating that its toxic effects had been successfully contained. Further experiments confirmed that LiPyDau worked through a unique mechanism: it formed permanent crosslinks between the two strands of DNA in cancer cells, causing irreparable damage and cell death. This approach differs from conventional chemotherapy drugs, which typically act by interfering with DNA replication or repair. Because of this, LiPyDau remained effective against tumour cells that had developed resistance to standard treatments, including those that overexpressed the P-glycoprotein pump responsible for expelling drugs from cells. The authors believe their formulation could be a major step forward for patients with cancers that no longer respond to therapy. Liposomal delivery is already used in some existing cancer drugs, but LiPyDau’s success in eradicating tumours suggests it may represent a new generation of chemotherapy design. Although these findings are limited to preclinical studies, the results indicate strong potential for future trials in humans. If proven safe and effective, LiPyDau could offer a powerful new option for treating aggressive and multidrug-resistant cancers, combining precision targeting with the intensity of traditional chemotherapy.